{"id":193154,"date":"2026-08-10T12:17:14","date_gmt":"2026-08-10T06:47:14","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=193154"},"modified":"2026-08-10T12:17:15","modified_gmt":"2026-08-10T06:47:15","slug":"poly-medicure-q1-results-fy27-pat-83-crore","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/poly-medicure-q1-results-fy27-pat-83-crore\/","title":{"rendered":"Poly Medicure Q1 FY27 Results: Revenue Rs 525 Cr, PAT Rs 83 Cr and Key Highlights"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>Poly Medicure Q1 FY27 results declared August 7, 2026. Revenue Rs 525 Cr (+30.30% YoY). PAT Rs 83 Cr (-8.76% YoY). CMP Rs 1693.8 (-0.91%).<\/em><\/p>\n<p>Poly Medicure Q1 FY27 results were announced on August 7, 2026, consolidated. Revenue grew +30.30% YoY to Rs 525 Cr from Rs 403 Cr in Q1 FY26. The broader <a href=\"https:\/\/univest.in\/indices\/bse-hc\/bse-healthcare-share-price-today\">BSE Healthcare<\/a> index reflected mixed sentiment during the quarter.<\/p>\n<p>Operating profit stood at Rs 88 Cr (+7.20% YoY). PAT came in at Rs 83 Cr (-8.76% YoY), offering a comprehensive view of how Poly Medicure is navigating the current medical devices environment.<\/p>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=poly-medicure-q1-fy27\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/poly-medicure-q1-results-fy27-pat-83-crore\/#Poly_Medicure_Q1_FY27_Financial_Highlights\" title=\"Poly Medicure Q1 FY27 Financial Highlights\">Poly Medicure Q1 FY27 Financial Highlights<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/poly-medicure-q1-results-fy27-pat-83-crore\/#Poly_Medicure_Q1_FY27_Performance_Analysis\" title=\"Poly Medicure Q1 FY27 Performance Analysis\">Poly Medicure Q1 FY27 Performance Analysis<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/poly-medicure-q1-results-fy27-pat-83-crore\/#Key_Business_Factors_in_Poly_Medicure_Q1_FY27_Results\" title=\"Key Business Factors in Poly Medicure Q1 FY27 Results\">Key Business Factors in Poly Medicure Q1 FY27 Results<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/poly-medicure-q1-results-fy27-pat-83-crore\/#Revenue_Expansion_Driving_Top-Line_Growth\" title=\"Revenue Expansion Driving Top-Line Growth\">Revenue Expansion Driving Top-Line Growth<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/poly-medicure-q1-results-fy27-pat-83-crore\/#Operating_Leverage_and_Margin_Improvement\" title=\"Operating Leverage and Margin Improvement\">Operating Leverage and Margin Improvement<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/poly-medicure-q1-results-fy27-pat-83-crore\/#PAT_Performance_and_Profitability_Trend\" title=\"PAT Performance and Profitability Trend\">PAT Performance and Profitability Trend<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/poly-medicure-q1-results-fy27-pat-83-crore\/#Dividend_Details\" title=\"Dividend Details\">Dividend Details<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/poly-medicure-q1-results-fy27-pat-83-crore\/#FY27_Outlook_for_Poly_Medicure\" title=\"FY27 Outlook for Poly Medicure\">FY27 Outlook for Poly Medicure<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/poly-medicure-q1-results-fy27-pat-83-crore\/#Poly_Medicure_Stock_Performance_After_Q1_FY27_Results\" title=\"Poly Medicure Stock Performance After Q1 FY27 Results\">Poly Medicure Stock Performance After Q1 FY27 Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/poly-medicure-q1-results-fy27-pat-83-crore\/#Key_Risks_for_Poly_Medicure\" title=\"Key Risks for Poly Medicure\">Key Risks for Poly Medicure<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/poly-medicure-q1-results-fy27-pat-83-crore\/#Sector-Specific_Risks\" title=\"Sector-Specific Risks\">Sector-Specific Risks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/poly-medicure-q1-results-fy27-pat-83-crore\/#Valuation_and_Earnings_Risk\" title=\"Valuation and Earnings Risk\">Valuation and Earnings Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/poly-medicure-q1-results-fy27-pat-83-crore\/#Operational_and_Financial_Risk\" title=\"Operational and Financial Risk\">Operational and Financial Risk<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/poly-medicure-q1-results-fy27-pat-83-crore\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/poly-medicure-q1-results-fy27-pat-83-crore\/#Frequently_Asked_Questions_on_Poly_Medicure_Q1_FY27_Results\" title=\"Frequently Asked Questions on Poly Medicure Q1 FY27 Results\">Frequently Asked Questions on Poly Medicure Q1 FY27 Results<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/poly-medicure-q1-results-fy27-pat-83-crore\/#When_were_Poly_Medicure_Q1_FY27_results_declared\" title=\"When were Poly Medicure Q1 FY27 results declared?\">When were Poly Medicure Q1 FY27 results declared?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/poly-medicure-q1-results-fy27-pat-83-crore\/#What_was_Poly_Medicure_revenue_in_Q1_FY27\" title=\"What was Poly Medicure revenue in Q1 FY27?\">What was Poly Medicure revenue in Q1 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/poly-medicure-q1-results-fy27-pat-83-crore\/#What_was_Poly_Medicure_PAT_in_Q1_FY27\" title=\"What was Poly Medicure PAT in Q1 FY27?\">What was Poly Medicure PAT in Q1 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/poly-medicure-q1-results-fy27-pat-83-crore\/#Did_Poly_Medicure_declare_a_dividend_in_Q1_FY27\" title=\"Did Poly Medicure declare a dividend in Q1 FY27?\">Did Poly Medicure declare a dividend in Q1 FY27?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/poly-medicure-q1-results-fy27-pat-83-crore\/#What_is_the_FY27_outlook_for_Poly_Medicure\" title=\"What is the FY27 outlook for Poly Medicure?\">What is the FY27 outlook for Poly Medicure?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/poly-medicure-q1-results-fy27-pat-83-crore\/#How_did_Poly_Medicure_stock_react_to_Q1_FY27_results\" title=\"How did Poly Medicure stock react to Q1 FY27 results?\">How did Poly Medicure stock react to Q1 FY27 results?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Poly_Medicure_Q1_FY27_Financial_Highlights\"><\/span><strong>Poly Medicure Q1 FY27 Financial Highlights<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width: 100%; border-collapse: collapse; font-size: 14px;\">\n<thead>\n<tr style=\"background: #0A0E1A; color: #ffffff;\">\n<th style=\"padding: 10px; text-align: left; border: 1px solid #DDD;\">Metric<\/th>\n<th style=\"padding: 10px; text-align: center; border: 1px solid #DDD;\">Q1 FY27 (Rs Cr)<\/th>\n<th style=\"padding: 10px; text-align: center; border: 1px solid #DDD;\">Q1 FY26 (Rs Cr)<\/th>\n<th style=\"padding: 10px; text-align: center; border: 1px solid #DDD;\">YoY Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 8px; border: 1px solid #DDD;\">Poly Medicure Revenue<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD;\">525<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD;\">403<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD; color: green;\">+30.30%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px; border: 1px solid #DDD;\">Operating Profit<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD;\">88<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD;\">82<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD; color: green;\">+7.20%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px; border: 1px solid #DDD;\">Net Profit (PAT)<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD;\">83<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD;\">91<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD; color: red;\">-8.76%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 8px; border: 1px solid #DDD;\">Reporting Basis<\/td>\n<td style=\"padding: 8px; text-align: center; border: 1px solid #DDD;\" colspan=\"3\">Consolidated<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Poly_Medicure_Q1_FY27_Performance_Analysis\"><\/span><strong>Poly Medicure Q1 FY27 Performance Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"margin-top: 24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for Live Data on This Stock<\/strong><\/a><\/p>\n<p>Poly Medicure Q1 FY27 results reflect modest fundamentals across key financial metrics. Revenue momentum stayed robust with the top line reaching Rs 525 Cr for the April to June 2026 quarter.<\/p>\n<p>Operating profit expanded +7.20% YoY to Rs 88 Cr. This indicates improving cost efficiency and better product mix.<\/p>\n<p>PAT of Rs 83 Cr marks a -8.76% YoY movement in Poly Medicure Q1 FY27 results. Investors monitoring Poly Medicure Q1 FY27 results will note this as a key FY27 performance milestone.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Business_Factors_in_Poly_Medicure_Q1_FY27_Results\"><\/span><strong>Key Business Factors in Poly Medicure Q1 FY27 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Revenue_Expansion_Driving_Top-Line_Growth\"><\/span><strong>Revenue Expansion Driving Top-Line Growth<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Poly Medicure Q1 FY27 results show top-line strength with revenue growing +30.30% YoY to Rs 525 Cr from Rs 403 Cr in Q1 FY26. Order execution momentum and market share gains in the Medical Devices segment fuelled this expansion.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Operating_Leverage_and_Margin_Improvement\"><\/span><strong>Operating Leverage and Margin Improvement<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Operating profit in Poly Medicure Q1 FY27 results improved +7.20% YoY to Rs 88 Cr, reflecting better cost control, improving product mix, and operating leverage as the company scales volumes.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"PAT_Performance_and_Profitability_Trend\"><\/span><strong>PAT Performance and Profitability Trend<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Net profit (PAT) in Poly Medicure Q1 FY27 results stood at Rs 83 Cr ((-8.76% YoY)). Near-term PAT moderation is being managed through cost optimisation and revenue diversification.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Dividend_Details\"><\/span><strong>Dividend Details<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>No dividend was announced alongside Poly Medicure Q1 FY27 results. The company is likely channelling earnings toward business reinvestment and working capital needs.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"FY27_Outlook_for_Poly_Medicure\"><\/span><strong>FY27 Outlook for Poly Medicure<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Following Poly Medicure Q1 FY27 results, management has reiterated a recovery-focused strategy targeting operational efficiencies, cost rationalisation, and revenue diversification. The pace of recovery in the medical devices segment will be a key monitorable for investors tracking Poly Medicure Q1 FY27 results. Consult a SEBI-registered financial advisor before making decisions.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Poly_Medicure_Stock_Performance_After_Q1_FY27_Results\"><\/span><strong>Poly Medicure Stock Performance After Q1 FY27 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p style=\"margin-top: 24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Poly Medicure live price and get daily stock recommendations.<\/em><\/p>\n<p>Poly Medicure shares were trading lower at Rs 1693.8 (-0.91%) on August 7, 2026, reflecting investor sentiment on the Poly Medicure Q1 FY27 results and near-term sector outlook. The CMP of Rs 1693.8 on the results date reflects broader market and sector sentiment in the medical devices space.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_for_Poly_Medicure\"><\/span><strong>Key Risks for Poly Medicure<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Sector-Specific_Risks\"><\/span><strong>Sector-Specific Risks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Regulatory approvals for new products and competition from imported devices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Valuation_and_Earnings_Risk\"><\/span><strong>Valuation and Earnings Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Sustained earnings pressure may delay re-rating; near-term earnings visibility remains limited.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Operational_and_Financial_Risk\"><\/span><strong>Operational and Financial Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Subsidiary-level losses or underperforming overseas operations could drag consolidated PAT lower.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Poly Medicure Q1 FY27 results reflect modest performance with revenue at Rs 525 Cr and PAT at Rs 83 Cr on a Consolidated basis. Operating leverage and sector tailwinds will determine the FY27 growth trajectory. Investors should review management commentary and sector developments before taking positions.<\/p>\n<div style=\"background: #CC0000; border-radius: 8px; padding: 16px 20px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 13px; line-height: 1.7; margin: 0;\"><strong style=\"color: #ffffff;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_on_Poly_Medicure_Q1_FY27_Results\"><\/span><strong>Frequently Asked Questions on Poly Medicure Q1 FY27 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"When_were_Poly_Medicure_Q1_FY27_results_declared\"><\/span><strong>When were Poly Medicure Q1 FY27 results declared?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Poly Medicure Q1 FY27 results were declared on August 7, 2026, covering the April to June 2026 quarter on a Consolidated basis.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_was_Poly_Medicure_revenue_in_Q1_FY27\"><\/span><strong>What was Poly Medicure revenue in Q1 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Poly Medicure Q1 FY27 results show revenue of Rs 525 Cr, +30.30% compared to Rs 403 Cr in Q1 FY26.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_was_Poly_Medicure_PAT_in_Q1_FY27\"><\/span><strong>What was Poly Medicure PAT in Q1 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Net profit in Poly Medicure Q1 FY27 results was Rs 83 Cr, -8.76% year-on-year.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Did_Poly_Medicure_declare_a_dividend_in_Q1_FY27\"><\/span><strong>Did Poly Medicure declare a dividend in Q1 FY27?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No dividend was announced alongside Poly Medicure Q1 FY27 results. Check the official NSE and BSE announcements for future dividend declarations.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_FY27_outlook_for_Poly_Medicure\"><\/span><strong>What is the FY27 outlook for Poly Medicure?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Management has guided operational restructuring and return to profitability for FY27. Sector trends and order visibility will be key monitorables for investors.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_did_Poly_Medicure_stock_react_to_Q1_FY27_results\"><\/span><strong>How did Poly Medicure stock react to Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Poly Medicure shares were trading lower at Rs 1693.8 (-0.91%) on August 7, 2026 following the Poly Medicure Q1 FY27 results. Always consult a SEBI-registered financial advisor before acting on stock price movements.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Poly Medicure Q1 FY27 results: Revenue Rs 525 Cr (+30.30% YoY), PAT Rs 83 Cr (-8.76% YoY). Key highlights, financial analysis and FY27 outlook.<\/p>\n","protected":false},"author":28,"featured_media":193153,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802],"class_list":["post-193154","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["193153"],"_edit_lock":["1786344439:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["74"],"rank_math_title":["Poly Medicure Q1 FY27 Results: Revenue Rs 525 Cr | PAT Highlights"],"rank_math_description":["Poly Medicure Q1 FY27 results: Revenue Rs 525 Cr (+30.30% YoY), PAT Rs 83 Cr (-8.76% YoY). Key highlights, financial analysis and FY27 outlook."],"rank_math_focus_keyword":["Poly Medicure Q1 FY27 results"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["35319"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/08\/poly-medicure-q1-results-fy27-pat-83-crore.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/193154","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=193154"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/193154\/revisions"}],"predecessor-version":[{"id":193167,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/193154\/revisions\/193167"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/193153"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=193154"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=193154"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=193154"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}